Our Mission to Cure Angelman Syndrome
The Foundation for Angelman Syndrome Therapeutics (FAST) was founded by families who refused to wait for someone else to change the future of Angelman syndrome. Today, that same urgency continues to shape how FAST approaches research, investment, and advocacy.
FAST is the leading patient advocacy organization working to cure Angelman syndrome.
As the largest non-governmental funder of Angelman syndrome research in the world, our goal is to drive forward transformative research and development programs for those living with Angelman syndrome — regardless of age or genotype.
How We Pursue Our Mission
We Start With What Science Needs Next
We support researchers with the tools and resources to advance promising Angelman syndrome science toward clinical readiness.
We Invest Where Progress Can Stall
We invest strategically to remove barriers, answer critical questions, and help promising Angelman syndrome research advance.
We Bring Families Into the Room
We elevate family voices to help shape the regulatory and policy decisions guiding Angelman syndrome treatment development.
What We Are Working Toward
A Future with More Possibility
Angelman syndrome can affect nearly every part of daily life and requires lifelong support. FAST is working toward a future in which meaningful treatments can change the course of Angelman syndrome and help individuals live more connected, capable, and independent lives.
The Science is Moving
From Research to Real Momentum
Angelman syndrome research has advanced dramatically since FAST was founded in 2008. Today, Angelman syndrome has one of the most active therapeutic development pipelines in rare disease.
POTENTIAL THERAPEUTIC PROGRAMS
SUPPORTED BY FAST
MISSION TO CURE ANGELMAN SYNDROME
How You Can Help
We Cannot Do This Without You
There is still more to discover, more to build, and more progress to make.
Your support allows FAST to continue investing where it can make the greatest difference, from early scientific questions to the tools, partnerships, and advocacy needed to help promising treatments advance.